Korean J Fam Pract. 2017; 7(3): 388-393  https://doi.org/10.21215/kjfp.2017.7.3.388
The Association between Benign Prostate Enlargement and Nonalcoholic Fatty Liver Disease
Young Ho Koh, Dong A Lee, Min Gou Song, Jae Bin Kim, Bo Reum Noh, Jung Hwan Lee*
Department of Family Medicine, Dongsuwon General Hospital , Suwon, Korea
Jung Hwan Lee
Tel: +82-31-210-0119
E-mail: comssaguru@naver.com
Received: May 2, 2016; Revised: September 19, 2016; Accepted: September 23, 2016; Published online: June 20, 2017.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Metabolic syndrome plays a potential role in the development of benign prostate enlargement. Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic component of metabolic syndrome. In this study, we evaluated the association between benign prostate enlargement and NAFLD in men who underwent a prostate health check-up in our center.
Methods: A total of 405 men who underwent transrectal ultrasonography at a health promotion center in Suwon from January 2011 to December 2014 were included in this retrospective study. Body measurements (height, weight, waist circumference, and body mass index), blood pressure, and blood tests (fasting glucose, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase) were obtained. Prostate volume was measured using transrectal ultrasonography and benign prostate enlargement was defined as prostate volume over 20 mL. All participants were separated into two groups, with or without NAFLD, using blinded abdominal ultrasonography.
Results: The prevalence of benign prostate enlargement and NAFLD was 50.4% (n=204) and 46.9% (n=190), respectively. The benign prostate enlargement group showed significantly greater age, weight, waist circumference, body mass index, AST, ALT, and prevalence of NAFLD (P<0.005). In multiple logistic regression analysis, the NAFLD group showed significantly higher prostate volumes than the group without NAFLD (odds ratio, 1.065; 95% confidence interval, 1.015–1.117; P=0.010).
Conclusion: Multiple logistic regression revealed independent correlations between NAFLD and prostate volume in this study. This suggests that increases in prostate volume and NAFLD are linked to a common etiopathogenic mechanism.
Keywords: Benign Prostate Enlargement; Non-Alcoholic Fatty Liver Disease; Metabolic Syndrome; Ultrasonography
References
  1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
    Pubmed CrossRef
  2. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001; 2: 297-301.
    Pubmed CrossRef
  3. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004; 172: 1390-3.
    Pubmed CrossRef
  4. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-8.
    Pubmed CrossRef
  5. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012; 2012: 145754.
    Pubmed KoreaMed CrossRef
  6. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138-43.
    Pubmed CrossRef
  7. Lee SY, Kim SK, Kwon CI, Kim MJ, Kang MS, Ko KH, et al. Clinical characteristics of health screen examinees with nonalcoholic fatty liver and normal liver function test. Korean J Gastroenterol 2008; 52: 161-70.
    Pubmed
  8. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-53.
    Pubmed KoreaMed CrossRef
  9. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
    Pubmed CrossRef
  10. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor's clothes fit? Diabetes Care 2004; 27:1011-2.
    Pubmed CrossRef
  11. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-203.
    Pubmed CrossRef
  12. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370: 89-93.
    Pubmed CrossRef
  13. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
    Pubmed CrossRef
  14. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
    CrossRef
  15. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
    Pubmed CrossRef
  16. Uzun H, Oğullar S, Ünal H, Zorba OÜ, Yazar S, Kalkan M. Non-alcoholic fatty liver disease is associated with benign prostate hyperplasia in men and with overactive bladder in women. Scand J Urol 2013; 47: 497-502.
    Pubmed CrossRef
  17. Russo GI, Cimino S, Fragalà E, Privitera S, La Vignera S, Condorelli R, et al. Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. World J Urol 2015; 33: 743-51.
    Pubmed CrossRef
  18. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
    CrossRef
  19. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990; 17: 477-86.
    Pubmed
  20. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604.
    CrossRef
  21. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
    Pubmed
  22. Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willett WC, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 1998;158: 2349-56.
    Pubmed CrossRef
  23. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
    CrossRef

This Article


Services
Social Network Service

e-submission

Archives